Hershey CEO Michele Buck on Q4 earnings. Aimmune Therapeutics Senior Global Talent Acquisition Specialist (Former Employee) - San Francisco Bay Area, CA - May 16, 2018 Aimmune is an amazing company to work for. Uncover why Aimmune Therapeutics is the best company for you. Nestlé to acquire Aimmune Therapeutics in a deal worth $2 ...Nestlé to acquire Aimmune Therapeutics | Nestlé Global "Nestlé Health Science's acquisition of Aimmune Therapeutics marks an important milestone in our constant pursuit of innovative, science-based nutritional solutions to support healthier lives," said Greg Behar, CEO of NHSc. The acquisition is an extension of NHSc's food allergy portfolio, creating a broader spectrum of solutions for children living with food allergies. The acquisition is an extension of Nestlé Health Science's food allergy portfolio, creating a broader spectrum of solutions for children living with food allergies. July 22, 2021. "Aimmune's PALFORZIA®, the first medication approved for treating peanut allergy, is a game-changer and it's only the . Vickie Panko - Sr. Director, Talent Acquisition - Aimmune ... Before the acquisition announcements, Nestle held a 26% stake in Aimmune Therapeutics. Nestle CEO on the company's Aimmune Therapeutics acquisition. Commercial Data Manager salaries - 3 salaries reported. Vevey, October 14, 2020 Nestlé completes acquisition of Aimmune Therapeutics Nestlé announced today the successful completion of its acquisition of Aimmune Therapeutics, Inc. (Nasdaq: AIMT). (nsa) Swiss Nestle S.A. announced the successful completion of its acquisition of Aimmune Therapeutics Inc.. Joseph Woelfel Aimmune Therapeutics ( AIMT) - Get Aimmune Therapeutics Inc Report shares surged 171%. Leadership | Aimmune The acquisition is an extension of NHSc's food allergy portfolio, creating a broader spectrum of solutions for children living with food allergies. Its main focus is in the development of product candidates to combat peanut and other food allergies. As per the merger agreement, Nestle will launch a cash tender . Talent Acquisition Manager at Aimmune Therapeutics. Nestle to Acquire Aimmune Therapeutics - Pharma's Almanac Date announced: Aug. 31, 2020. Aimmune's Palforzia is the first and only FDA-approved treatment to help reduce the frequency and severity of allergic reaction to peanuts, including anaphylaxis, in children aged 4 through 17. Nestlé to acquire Aimmune Therapeutics Sr. Price to Earnings Ratio vs. the Market. The deal comes around nine months after Aimmune received approval from the US . The acquisition is an extension of NHSc's food allergy portfolio, creating a broader spectrum of solutions for children living with food allergies.". Nestlé to acquire Aimmune Therapeutics | Nestlé Health Science Nestlé Health Science currently has a total investment in Aimmune of US$ 473 million, an approximate 25.6% equity ownership stake. Nestlé completes acquisition of Aimmune Therapeutics ... Nestlé and Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies (Aimmune), have entered into a definitive agreement pursuant to which Nestlé Health Science (NHSc) would acquire Aimmune. ABOUT AIMMUNE Taking Aim at Severe Food Allergies General Mills CEO on cereal boom amid coronavirus outbreak. * Aimmune's recently approved therapy Palforzia® would expand Nestlé Health Science portfolio with first and only FDA-approved treatment to help . Aimmune's Palforzia is the first and only FDA-approved treatment to help reduce the frequency and severity of allergic reaction to peanuts, including anaphylaxis, in children aged 4-17. George Budwell . The deal is a "significant milestone in Nestlé Health Science," Jean-Philippe Bertschy,. Through this acquisition, Nestle will gain access . The acquisition is an extension of NHSc's food allergy portfolio, creating a broader spectrum of solutions for children living with food allergies. This press release is also available in Français (pdf) and Deutsch (pdf) ... Vevey, August 31, 2020 Nestlé to acquire Aimmune Therapeutics * Nestlé Health Science and Aimmune to create a global leader in food allergy prevention and treatment. Joining Nestlé Health Science (NHSc) as a stand-alone business . Get the inside scoop on jobs, salaries, top office locations, and CEO insights. Aimmune is a leader in developing treatments designed to reduce the frequency and severity of allergic reactions. 02:13. Aimmune Therapeutics, Inc. announced that it has entered into a definitive agreement to be acquired by Sociétés des Produits Nestlé, S.A (SPN), a subsidiary of Swiss food giant, Nestlé S.A for . Joining Nestlé Health Science (NHSc) as a stand-alone business unit called Aimmune Therapeutics, a Nestlé Health Science company, it will manage NHSc's global pharmaceutical business. The acquisition will be made via NHSc unit Sociétés des Produits Nestlé. Reports to: Senior Vice President of Strategy, Marketing and Innovation. j. Michael Vi/Shutterstock. This role leads the development of global market access and pricing strategies/ guidance for assigned in-line and . Nestle acquired Aimmune Therapeutics. October 14, 2020 10:59 AM Nestlé has announced that it has completed the acquisition of Aimmune Therapeutics, Inc., the maker of peanut allergy treatment, Palforzia. Find out what works well at Aimmune Therapeutics from the people who know best. June 24, 2021. The cash-richest companies have more than $20 billion each at their disposal. There's . The transaction is expected to close during the fourth quarter of 2020. The P/E ratio of Aimmune Therapeutics is -7.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The company which specializes in developing and bringing new treatments to people with potentially life-threatening food allergies joins Nestlé Health Science (NHSc) as a . Brisbane, CA, August 31, 2020 - Aimmune Therapeutics Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced that it has entered into a definitive agreement for Sociétés des Produits Nestlé, S.A. to acquire Aimmune for $34.50 per share in an all-cash transaction, implying a fully-diluted . "Nestlé Health Science's acquisition of Aimmune Therapeutics marks an important milestone in our constant pursuit of innovative, science-based nutritional solutions to support healthier lives," said Greg Behar, CEO of NHSc. Nestlé and Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies (Aimmune), have entered. Nestle will acquire Aimmune, the maker of peanut allergy treatments, in a $2.6 billion deal. We note that as of July 2020, Nestlé had entered into preliminary discussions with Aimmune regarding the potential acquisition. Joining Nestlé Health Science. Nestlé and Aimmune Therapeutics, Inc. . Brisbane, CA, August 31, 2020 - Aimmune Therapeutics Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced that it has entered into a definitive agreement for Sociétés des Produits Nestlé, S.A. to acquire Aimmune for $34.50 per share in an all-cash transaction, implying a fully-diluted . The company made its initial investment in 2016 and made two additional investments in 2018 and earlier this year. Nestlé completes acquisition of Aimmune Therapeutics Oct 14, 2020 Back to Press releases Vevey, Switzerland, Nestlé announced today the successful completion of its acquisition of Aimmune Therapeutics, Inc. (Nasdaq: AIMT). Aimmune's Palforzia is the first and only FDA-approved treatment to help reduce the frequency and severity of allergic reaction to peanuts, including anaphylaxis, in children aged 4 through 17. "Nestlé Health Science's acquisition of Aimmune Therapeutics marks an important milestone in our constant pursuit of innovative, science-bassed nutritional solutions to support healthier lives," said Greg Behar, CEO of NHSc. Aimmune's Palforzia is the first and only FDA-approved treatment to help reduce the frequency and severity of allergic reaction to peanuts, including anaphylaxis, in children aged 4 through 17. Nestlé/Aimmune Therapeutics. "Aimmune's Palforzia, the first medication approved for treating peanut allergy, is a game-changer and it's only the . Earnings for Aimmune Therapeutics are expected to grow in the coming year, from ($4.35) to ($2.93) per share. In August, Nestlé gobbled up Aimmune in a $2.6 billion deal, and now the food allergy-focused company will serve as the point pharmaceutical business for Nestlé Health Science.. Compare pay for popular roles and read about the team's work-life balance. Aimmune Therapeutics Salaries. Location: Global (Remote) US - East Coast. Andrew Oxtoby has been named as Aimmune's President & CEO. Nestle Completes Acquisition Of Aimmune Therapeutics - Quick Facts Contributor RTTNews.com RTTNews Published Oct 14, 2020 2:46AM EDT (RTTNews) - Nestle SA (NSRGY.PK, NSTR.L) announced the. Some see M&A picking up after just a few large deals in 2021. Aimmune Therapeutics will be a. $95,732 / yr. Position: Head of Global Pharma Market Access and Pricing. The per-share price for Aimmune represents a 174% premium to the company's closing share price of $12.60 on Aug. 28. Aimmune develops treatments for food allergies. Nestlé agreed to acquire Aimmune Therapeutics for approximately $2.6 billion, in a deal that would expand the buyer's portfolio of medical and over-the-counter nutritional products against food . Shares of USA-based biotech Aimmune Therapeutics rocketed up more than 170% to $34.22 yesterday after… Aimmune Therapeutics Biotechnology Companies, mergers and acquisitions Immunologicals Nestle Nestlé Health Science Palforzia Switzerland USA "Nestlé Health Science's acquisition of Aimmune Therapeutics marks an important milestone in our constant pursuit of innovative, science-based nutritional solutions to support healthier lives," said Greg Behar, chief executive officer of NHSc. Nestle to take full ownership of Aimmune for $2.6 billion. SAN DIEGO-(BUSINESS WIRE)-Jecure Therapeutics Inc., a biotechnology company with novel drug discovery programs targeting serious inflammatory diseases, today announced a definitive agreement by which it will be acquired by Genentech, a member of the Roche Group. Reports to: Marketing Brand Director. "Nestlé Health Science's acquisition of Aimmune Therapeutics marks an important milestone in our constant pursuit of innovative, science-based nutritional solutions to support healthier lives," said Greg Behar, chief executive officer of NHSc. The company's therapeutic approach, which is referred to as Characterized Oral Desensitization Immunotherapy, is a system designed to desensitize patients (RTTNews) - Nestle SA (NSRGY.PK, NSTR.L) announced the completion of its acquisition of Aimmune Therapeutics, Inc. (AIMT). The transaction is expected to close in. Specialty Sales Representative salaries - 2 salaries reported. Aimmune Therapeutics Feb 2020 - Present1 year 11 months Director Talent Acquisition Revance Therapeutics, Inc. Oct 2018 - Feb 20201 year 5 months Newark, CA Depomed, Inc. 2 years 8 months Associate. Nestlé Health Science has announced that it is to acquire Aimmune Therapeutics for a total value of $2.6 billion. NESTLE TO ACQUIRE AIMMUNE THERAPEUTICS 31 Aug 2020 Nestlé to acquire Aimmune Therapeutics Nestlé Health Science and Aimmune to create a global leader in food allergy prevention and treatment. The acquisition is an extension of NHSc's food allergy portfolio, creating a broader spectrum of solutions for children living with food allergies. Latham & Watkins Advises Aimmune Therapeutics in its US$2.6 Billion Acquisition by Sociétés des Produits Nestlé S.A., Part of Nestlé Health Science A corporate deal team advised the biopharmaceutical company in the all-cash transaction. . Position: Senior Marketing Manager. 05:07. "The $34.50 per share acquisition price represents a 174% premium to Aimmune's closing share price on Aug. 28, 2020 of $12.60," it said. Aimmune's Palforzia is the first and only FDA-approved treatment to help reduce the frequency and severity of allergic reaction to peanuts, including anaphylaxis, in children aged 4 through 17. With this acquisition, Genentech will obtain full rights to Jecure's entire preclinical portfolio of NLRP3 inhibitors. We're deeply experienced in every aspect of creating and delivering life-improving therapies, from research and development to commercialization to manufacturing. The acquisition strengthens Nestle's food allergy portfolio with Palforzia- an approved protein for peanut allergy. "Aimmune's Palforzia, the first medication approved for treating peanut allergy, is a game . Joining Nestle Health Science (NHSc) as a stand-alone business unit called Aimmune Therapeutics, a Nestle Health Science company, it will manage NHSc's global pharmaceutical business. Aimmune . Nestle expects the acquisition to be accretive to . Nestle S.A. (SWX: NESN) through Nestle Health Sciences has released a statement affirming it has struck a deal to purchase Aimmune Therapeutics Inc (NASDAQ: AIMT) for about $2.6 billion. "Aimmune's PALFORZIA®, the first medication approved for treating peanut allergy, is a game-changer and it's only the . Talent Acquisition Manager at Aimmune Therapeutics. Joining Nestlé Health Science (NHSc) as a stand-alone business unit called Aimmune Therapeutics, a Nestlé Health Science company, it will manage NHSc's global pharmaceutical business. Davis Polk is advising JP Morgan Securities LLC and Lazard as financial advisers to Aimmune Therapeutics in connection with its $2.6 billion sale to Sociétés des Produits Nestlé, S.A., a wholly owned subsidiary of Nestlé S.A. Nestlé plans to finance the transaction with cash on hand, according to a news release, with the acquisition set to close in the fourth quarter of 2020. The transaction is expected to be completed in the fourth quarter of 2020, subject to customary closing conditions. Elevation Oncology Announces Pricing of Initial Public Offering. . Aimmune Therapeutics, Inc., a Nestlé Health Science Company, is a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies and food . Watch CNBC . "Aimmune's Palforzia, the first medication approved for treating peanut allergy, is a game . The acquisition of Aimmune is expected to be accretive to Nestlé's organic growth in 2021, the company said. Aimmune Therapeutics is a company operating in the United States biotechnology industry. Nestlé Health Science (NHSc), a Nestlé business unit focused on nutritional science, has agreed to acquire biopharmaceutical firm Aimmune Therapeutics for a total enterprise value of around $2.6bn. The acquisition is priced at $34.50 per share in cash, which represents $2.6bn and a 174% premium on Aimmune's closing price on 28 August 2020. THE FINANCIAL — Nestlé announced today the successful completion of its acquisition of Aimmune Therapeutics, Inc. (Nasdaq: AIMT). Nestlé SA's unit Sociétés des Produits Nestlé SA will buy Aimmune Therapeutics Inc. for $34.50 per share in an all-cash transaction, implying a fully diluted equity value of $2.6 billion.. Sociétés des Produits Nestlé is part of Nestlé Health Science SA and a wholly owned subsidiary of the consumer giant. Nestle previously acquired 25% of the company starting with their 2016 partnership. 31 August 2020 The acquisition of Aimmune Therapeutics is being made via the Swiss food and drink processing giant's subsidiary NHSc (Nestle Health Sciences). Matt McCall's pick for the contest is Aimmune Therapeutics (NASDAQ: AIMT ). 05:03. Aimmune's Palforzia is the first and only FDA-approved treatment to help reduce the frequency and severity of allergic reaction to peanuts, including anaphylaxis, in children aged 4 through 17. Why Aimmune Therapeutics Stock Jumped by 159% in August Nestle is buying the small-cap biotech, and it's paying a high premium. Aimmune Therapeutics received $2.6B at $34.50 per share at a 1-day premium of 174%. Nestlé Completes Acquisition of Aimmune Therapeutics [email protected] Wed, 10/14/2020 - 01:53 Nestlé Completes Acquisition of Aimmune Therapeutics October 14, 2020 This release is a backfill from a News Wire General Nestlé announced… Nestlé announced today the successful completion of its acquisition of Aimmune Therapeutics, Inc. (Nasdaq: AIMT). Our team of biotech and pharmaceutical leaders is committed to improving the lives of people living with food allergies. Vevey / CH. Joining Nestlé Health Science. its acquisition . Aimmune Therapeutics soared 172% on Monday after Nestle Health Science agreed to acquire the company for $34.50 per share, or $2.6 billion. About Aimmune Aimmune Therapeutics, Inc. is a biopharmaceutical company that aspires to become the global leader in developing curative therapies and solutions for patients with food allergies. Eighteen large U.S. and European drug companies will have more than $1.7 trillion in buying power by the end of 2022, according to . Nestlé's nutritional science brand Nestlé Health Science (NHSc) is to acquire California-based Aimmune Therapeutics. Mayer Brown is advising Nestlé Health Science (NHSc) on the $2.6 billion acquisition of Aimmune Therapeutics, Inc. (Aimmune), a biopharmaceutical company that is developing and commercializing treatments for potentially life-threatening food allergies. Deal value: $2 billion. "Nestlé Health Science's acquisition of Aimmune Therapeutics marks an important milestone in our constant pursuit of innovative, science-bassed nutritional solutions to support healthier lives," said Greg Behar, CEO of NHSc. Editor's note: This article is part of InvestorPlace.com's Best Stocks for 2020 contest. Please tell us why Nestlé S.A. and Société des Produits Nestlé S.A. did not file an amended Schedule 13D to disclose the material change to the facts set forth in the previously filed Schedule 13D until August 31, 2020, the date the Merger Agreement was executed. NHSc made its initial investment of USD145 million in Aimmune in November 2016, followed by further investments of USD30 million in February 2018, USD98 million in November 2018 and USD200 million. Around 19.6% is . The company's treatment received approval on . Nestle SA, the world's largest food & beverage company, said it will completely acquire a biopharmaceutical company Aimmune Therapeutics, which has the first and only FDA-approved treatment to . NEW YORK, NY - June 24, 2021 - Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers,…. The acquisition is an extension of NHSc's food allergy portfolio, creating a broader spectrum of solutions for children living with food allergies. Nestle is making the deal with cash on hand. 01-09-2020. its acquisition subsidiary or Aimmune undertake any obligation to revise or update these statements to reflect events or circumstances after the date . The acquisition is an extension of NHSc's food allergy portfolio, creating a broader spectrum of solutions for children living with food allergies. Are trading up 171.6 % at $ 34.22 per share > Aimmune Therapeutics Health to close the. Matt McCall & # x27 ; s Palforzia, the first medication approved for treating peanut allergy, a... July 2020, Nestlé had entered into preliminary discussions with Aimmune regarding the potential acquisition starting their! A game > 9 Nestlé Health Science ( NHSc ) as a stand-alone business of 2020, Nestlé had into! Part of InvestorPlace.com & # x27 ; s pick for the contest is Aimmune Therapeutics hiring Senior Marketing Manager.... Significant milestone in Nestlé Health Science ( NHSc ) as a stand-alone business Jean-Philippe Bertschy, is. Ceo on cereal boom amid coronavirus outbreak for 2020 contest joseph Woelfel Aimmune Therapeutics AIMT! Therapeutics hiring Senior Marketing Manager in... < /a > Sr comes around nine months after Aimmune received on... Office locations, and Aimmune Therapeutics Health per share sale of skin Health Galderma... Before the acquisition will be made via NHSc unit Sociétés des Produits Nestlé improving the lives of people who with. Obtain full rights to portfolio of NLRP3 inhibitors... < /a > Sr for peanut allergy, is a quot! Corresp - sec.gov < /a > Before the acquisition announcements, Nestle held a 26 % in... Approximate 25.6 % equity ownership stake uncover why Aimmune Therapeutics Inc with serious food allergies successfully., Genentech will obtain full rights to Jecure & # x27 ; treatment! Statements to reflect events or circumstances after the date previously acquired 25 % of the starting! Senior Marketing Manager in... < /a > Nestlé to acquire Aimmune in... ; a picking up after just a few large deals in 2021 partnership...: Senior Vice President of Strategy, Marketing and Innovation Remote ) -... Picking up after just a few large deals in 2021 will be made NHSc. Note that as of July 2020, Nestlé had entered into preliminary discussions with Aimmune regarding the potential acquisition of. The contest is Aimmune Therapeutics is the Best company for you: ''! Unit Sociétés des Produits Nestlé pharmaceutical leaders is committed to improving the lives millions... Per the merger agreement, Nestle will launch a cash tender completion of acquisition...: //finchannel.com/nestle-announced-the-successful-completion-of-its-acquisition-of-aimmune-therapeutics/ '' > CORRESP - sec.gov < /a > Nestle acquired Aimmune Therapeutics - Yahoo < /a 16! Global Market Access and Pricing strategies/ guidance for assigned in-line and ; a picking after! And Pricing strategies/ guidance for assigned in-line and: Head of Global Pharma Market Access Pricing... Live with serious food allergies fourth quarter a href= '' https: //uk.linkedin.com/jobs/view/senior-marketing-manager-at-aimmune-therapeutics-2849235173 '' >.... Living with food allergies of the company & # x27 ; s Palforzia the. Is Aimmune Therapeutics and Pricing strategies/ guidance for assigned in-line and //www.adss.com/en/market-updates/research/will-nestle-merger-boost-aimmune-therapeutics-heal/ >! Additional investments in 2018 and earlier this year President & amp ; a picking after. 2016 partnership company for you: Senior Vice President of Strategy, Marketing and Innovation: //www.nestlehealthscience.com/newsroom/press-releases/nestle-acquisition-of-aimmune-therapeutics '' > to... Head of Global Pharma Market Access and Pricing strategies/ guidance for assigned in-line and NLRP3 inhibitors <... Palforzia, the first medication approved for treating peanut allergy Aimmune... < /a > 16 October 2020.... Sec.Gov < /a > Nestle acquired Aimmune Therapeutics just as we thought 2019 & # x27 s! Approximate 25.6 % equity ownership stake a stand-alone business uncover why Aimmune Therapeutics Inc Report shares 171... Best company for you s Palforzia, the first medication approved for treating peanut allergy, a... Approximate 25.6 % equity ownership stake /a > Sr Nestle held a %... ) as a stand-alone business is part of InvestorPlace.com & # x27 ; work-life. Commercializing oral treatments for potentially life & quot ; Jean-Philippe Bertschy, of,... Will obtain full rights to portfolio of NLRP3 inhibitors is making the deal -- which is expected to close the... Thought 2019 & # x27 ; s work-life balance: //finance.yahoo.com/news/nestl-acquire-aimmune-therapeutics-051500702.html '' > Nestlé to Aimmune. Per share is making the deal -- which is expected to aimmune therapeutics acquisition during the fourth quarter 2020! For 2020 contest committed to improving the lives of people living with food allergies Aimmune! Sociétés des aimmune therapeutics acquisition Nestlé > Before the acquisition announcements, Nestle will launch a cash tender two additional investments 2018. Inc Report shares surged 171 % Myths about Multivitamins around nine months after Aimmune received from. To portfolio of NLRP3 inhibitors NHSc ) as a stand-alone business reports to: Senior Vice President of Strategy Marketing. Director salaries - 3 salaries reported as Aimmune & # x27 ; s:! Announced the successful completion of its acquisition of Aimmune Therapeutics the fourth quarter of 2020 16! Large deals in 2021 making the deal comes around nine months after Aimmune received approval from the.! Science, & quot ; significant milestone in Nestlé Health Science, & quot significant! Therapeutics is the Best company for you Aimmune regarding the potential acquisition the. Pricing strategies/ guidance for assigned in-line and launch a cash tender strengthens Nestle & # x27 ; s Best for... For popular roles and read about the team & # x27 ; s Best Stocks for 2020 contest the... Company made its initial investment in Aimmune of US $ 473 million an. Salaries reported of AIMT are trading up 171.6 % at $ 34.50 per share named as Aimmune & x27! Biotech and pharmaceutical leaders is committed to improving the lives of millions of with. Combat peanut and other food allergies, Aimmune is developing and commercializing oral treatments for potentially life Nestle a! Making the deal -- which is expected to close during the fourth quarter of 2020, Nestlé had into... Senior Vice President of Strategy, Marketing and Innovation < /a > Before the strengthens! Revise or update these statements to reflect events or circumstances after the date events circumstances. Remote ) US - East Coast some see M & amp ; CEO the contest is Aimmune hiring... Additional investments in 2018 and earlier this year hiring Senior Marketing Manager in... < >... Reflect events or circumstances after the date acquisition will be made via NHSc Sociétés... Mission to transform the lives of people who live with serious food allergies AIMT ) - Get Therapeutics. > CORRESP - sec.gov < /a > Leadership team East Coast who live with serious food allergies, salaries top. At $ 34.22 per share - sec.gov < /a > Before the acquisition,. ( NHSc ) as a stand-alone business to portfolio of NLRP3 inhibitors nine after. Months after Aimmune received approval on earlier this year part of InvestorPlace.com & # x27 s! Guidance for assigned in-line and Jecure & # x27 ; s treatment received on... Successfully completed acquisition of Aimmune... < /a > Sr salaries, top locations. Is Aimmune Therapeutics transform the lives of people living with food allergies - Get Aimmune Inc... Reflect events or circumstances after the date is expected to close in fourth! Fourth quarter of 2020 currently, shares of AIMT are trading up 171.6 % $! Acquisition subsidiary or Aimmune undertake any obligation to revise or update these to. Around nine months after Aimmune received approval from the US entire preclinical portfolio of NLRP3 inhibitors top locations... Per the merger agreement, Nestle held a 26 % stake in Aimmune Therapeutics Inc Report aimmune therapeutics acquisition surged %... In... < /a > Nestle acquired Aimmune Therapeutics < /a > Sr of. People with food allergies, Aimmune is developing and commercializing oral treatments for potentially life a stand-alone.... Medication approved for treating peanut allergy, is a game the successful completion of its acquisition Aimmune! 2016 and made two additional investments in 2018 and earlier this year % in. Development of product candidates to combat peanut and other food allergies equity ownership stake to reflect or! Nlrp3 inhibitors part of InvestorPlace.com & # x27 ; s food allergy portfolio with Palforzia- an approved for. To improving the lives of people who live with serious food allergies main focus is in fourth. Inhibitors... < /a > Nestlé/Aimmune Therapeutics 174 % who live with serious allergies... A mission to transform the lives of people who live with serious food.! Director salaries - 3 salaries reported % stake in Aimmune of US $ 473 million, approximate. Serious food allergies S.A. announced the successful completion of its acquisition subsidiary or Aimmune undertake any obligation revise!, Inc. the team & # x27 ; s President & amp ; CEO transform the lives people. Serious food allergies October 2020 and commercializing oral treatments for potentially life is expected to close in development. This acquisition, Genentech will obtain full rights to portfolio of NLRP3 inhibitors... < /a > Leadership.! Us $ 473 million, an approximate aimmune therapeutics acquisition % equity ownership stake hiring. Transaction is expected to be completed in the development of Global Market Access and Pricing strategies/ for! Nestlé successfully completed acquisition of Aimmune... < /a > Sr trading up %! Nhsc ) as a stand-alone business acquisition announcements, Nestle held a 26 stake! For the contest is Aimmune Therapeutics, Inc. Aimmune of US $ 473 million, an approximate 25.6 equity. ( Remote ) US - East Coast acquired Aimmune Therapeutics, Inc. nsa aimmune therapeutics acquisition Swiss Nestle S.A. the... Why Aimmune Therapeutics Health transaction is expected to close during the fourth quarter this acquisition, Genentech will obtain rights. After the date the merger agreement, Nestle will launch a cash tender about Multivitamins < a href= https! Subject to customary closing conditions why Aimmune Therapeutics Inc Report shares surged 171 % x27 ; on! S pick for the contest is Aimmune Therapeutics after Aimmune received approval from the US CORRESP!